A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Latest Information Update: 25 Oct 2024
At a glance
- Drugs TQB 2252 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 25 Oct 2024 New trial record